SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 29, 2000
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
Biocontrol Technology, Inc. announced today that its
subsidiary, IDT, Inc., has formed a strategic and
corporate development alliance with Capital Management
Consulting, Inc. (Capital) to position the Company for
growth, development, and partnerships. Capital
specializes in the design and implementation of value-
creating strategy for the medical products industry.
Located in Boston, MA, Capital's strategic development
and advisory services have impacted portfolios,
partnerships, and acquisitions with an aggregate value
in excess of $10 billion.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - Press Release.
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: February 29, 2000
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.429.0673 phone
1.412.279.9690 fax 1.412.279.5041 fax
BIOCONTROL TECHNOLOGY, INC. SUBSIDIARY, IDT, INC. AND CAPITAL
MANAGEMENT CONSULTING, INC. FORM STRATEGIC AND CORPORATE
DEVELOPMENT ALLIANCE
Pittsburgh, PA - February 29, 2000 - Biocontrol Technology,
Inc. (OTCBB:BICO) announced today that its subsidiary, IDT, Inc.,
has formed a strategic and corporate development alliance with
Capital Management Consulting, Inc. (Capital) to position the
Company for growth, development, and partnerships.
Capital specializes in the design and implementation of
value-creating strategy for the medical products industry.
Located in Boston, MA, Capital's strategic development and
advisory services have impacted portfolios, partnerships,
and acquisitions with an aggregate value in excess of $10
billion.
Joseph Kozikowski, M.D., who has extensive experience in
designing and executing clinical development programs, product
registrations, and strategic alliances, will lead Capital's IDT
team. Dr. Kozikowski studied business at Harvard Business
School, law at The Food and Drug Law Institute, and medicine at
The Johns Hopkins University School of Medicine. Richard
Morroney, who will provide regulatory affairs and product
development expertise, has led numerous successful FDA
submissions and has successfully developed and implemented
medical product quality systems and strategies. Thong Q. Le, who
will provide business and market development expertise, has
extensive experience in strategic alliances, market analysis, and
finance. Mr. Le studied business and economics at the Templeton
College Graduate School of Business Administration of Oxford
University and at Harvard University.
In January 2000, IDT announced that, in conjunction with
HemoCleanse, Inc., FDA clearance has been obtained to market
the ThermoChem-HTT System and related disposables with
intended use to raise the core temperature of the peritoneum
to the desired temperature in the 41 C (105.8 F) to 42 C
(107.6 F) range by continuously bathing the peritoneum with
circulating sterile solutions. The ThermoChem-HT System
will now be available to help standardize a revolutionary
cancer treatment of ovarian, gastrointestinal, and other
tumors that have spread to the lining surface of the abdomen
and pelvis. IDT, again in conjunction with HemoCleanse,
Inc., also announced in mid-February 2000 that it has
received FDA approval and Institutional Review Approval from
the University of Texas Medical Branch at Galveston to
continue a human clinical trial to treat patients with non-
small cell lung cancer.
Biocontrol Technology has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products. IDT, Inc. a
subsidiary of Biocontrol also located in Pittsburgh, PA, holds
exclusive worldwide marketing rights to the ThermoChem-HT
technology and related disposables for regional hyperthermia and
ThermoChem technology and related disposables for whole body
hyperthermia.
WEBSITE: www.bico.com
